(the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic ...

The first presentation will spotlight JR-479, an investigational BBB-penetrating β-Hexosaminidase A (rDNA origin) enzyme replacement therapy (ERT) that JCR is developing for the treatment of people ...

SEATTLE, Jan. 22, 2025 (GLOBE NEWSWIRE) -- ("Perspective" or the "Company") (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers through ...

The battle for Delhi has begun, with the Aam Aadmi Party (AAP) and the Bharatiya Janata Party (BJP) engaging in a fierce poster war ahead of the assembly polls ... (Only the headline and picture of ...